Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 116.18 (-0.36), GILD: 81.79 (-1.20), PFE: 34.75 (+0.25), AMGN: 149.42 (-1.23), ABBV: 59.98 (-0.13), RDY: 45.60 (-0.24), AVXS: 43.26 (+0.65), NVS: 79.46 (+0.79)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 28.31 (-3.66), CLSN: 1.29 (-0.01), JAZZ: 141.92 (-2.39)
Corcept's (CORT) Q4 Earnings Impress, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 10:00AM CST
Corcept Therapeutics Incorporated (CORT) reported earnings of 1 cent per share in the fourth quarter of 2015, while Zacks Consensus Estimates was a loss of 2 cents
PETX: 6.13 (-0.01), TRIL: 9.54 (-0.39), CORT: 5.41 (-0.16)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 8.60 (-0.09), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 8.42 (-0.21), BXLT: 46.02 (-0.18), ARNA: 1.87 (-0.03)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 8.42 (-0.21), BXLT: 46.02 (-0.18), ARNA: 1.87 (-0.03)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 141.92 (-2.39), TEVA: 50.98 (-0.99), CNCE: 10.79 (+0.39)
Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 10:35AM CDT
Corcept Therapeutics (CORT) posted loss of a penny per share in the second quarter of 2015, narrower than both the Zacks Consensus Estimate of a loss of 5 cents.
VRX: 21.64 (-0.88), ANAC: 99.20 (-0.06), CORT: 5.41 (-0.16)
Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 8:10AM CDT
Although Arena Pharmaceuticals' (ARNA) second quarter loss was narrower-than-expected, revenues missed expectations.
GILD: 81.79 (-1.20), ARNA: 1.87 (-0.03)
Will Epizyme (EPZM) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 12:40PM CDT
Epizyme (EPZM) has an Earnings ESP of 3.08% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
INO: 11.26 (+0.06), EPZM: 10.92 (-0.04), GSK: 41.65 (+0.16)
Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 12:00PM CDT
Investor focus will remain on the performance of Arena's (ARNA) obesity treatment - Belviq.
BDSI: 2.44 (+0.08), VVUS: 1.11 (-0.05), ARNA: 1.87 (-0.03)